A Phase 1 Proof of Concept Study Evaluating Intravitreal AAVCAGsCD59 for the Treatment of Wet Age-Related Macular Degeneration (AMD)
Phase of Trial: Phase I
Latest Information Update: 10 Jan 2019
At a glance
- Drugs HMR-59 (Primary) ; Aflibercept; Bevacizumab; Prednisolone; Ranibizumab
- Indications Wet age-related macular degeneration
- Focus Proof of concept; Therapeutic Use
- Sponsors Hemera Biosciences
- 06 Jan 2019 Planned number of patients changed from 10 to 25.
- 13 Sep 2018 Status changed from not yet recruiting to recruiting.
- 01 Sep 2018 Planned initiation date changed from 6 Aug 2018 to 14 Sep 2018.